Plasma lysozyme as surrogate biomarker for detection of coronary artery disease in patients without Standard Modifiable Cardiovascular Risk Factors (SMuRFless)
Wycombe Hospital, Buckinghamshire (United Kingdom of Great Britain & Northern Ireland)
0
follower
7
more
presentations
in this session
Unlocking the inflammatory 'code' in multivessel coronary disease: pathological network mediated by the PCSK9-NLRP3 axis and a novel microcirculatory dysfunction prediction model